WO2007054950A1 - A process for the preparation of highly pure (e) n,n-diethyl-2-cyano-3-(3,4-dihydroxy- 5-nitro phenyl) acrylamide (entacapone) - Google Patents

A process for the preparation of highly pure (e) n,n-diethyl-2-cyano-3-(3,4-dihydroxy- 5-nitro phenyl) acrylamide (entacapone) Download PDF

Info

Publication number
WO2007054950A1
WO2007054950A1 PCT/IN2005/000363 IN2005000363W WO2007054950A1 WO 2007054950 A1 WO2007054950 A1 WO 2007054950A1 IN 2005000363 W IN2005000363 W IN 2005000363W WO 2007054950 A1 WO2007054950 A1 WO 2007054950A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
organic
dihydroxy
diethyl
cyano
Prior art date
Application number
PCT/IN2005/000363
Other languages
French (fr)
Inventor
Venkatasubramanian Radhakrishnan Tarur
Dhananjay Govind Sathe
Nandu Baban Bhise
Avinash Venkatraman Naidu
Umesh Parashram Aher
Sachin Shivaji Patil
Original Assignee
Usv Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usv Limited filed Critical Usv Limited
Priority to PCT/IN2005/000363 priority Critical patent/WO2007054950A1/en
Priority to AT05826478T priority patent/ATE445591T1/en
Priority to DE602005017204T priority patent/DE602005017204D1/en
Priority to US12/092,657 priority patent/US20080319226A1/en
Priority to EP05826478A priority patent/EP1945607B1/en
Publication of WO2007054950A1 publication Critical patent/WO2007054950A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/32—Separation; Purification; Stabilisation; Use of additives
    • C07C253/34—Separation; Purification

Definitions

  • the invention relates to a process for the preparation of highly pure (E) N,N-diethyl-2-cyano- 3-(3,4-dihydroxy-5-nitro phenyl) acrylamide (Entacapone) of the formula I:
  • Process for the preparation of N, N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitro phenyl) acrylamide comprises condensation of 3,4-dihydroxy-5-nitro benzaldehyde and N 9 N- hydrochloric diethyl cyanoacetamide in the presence of piperidine-acetate in dry ethanol (Example 100).
  • the condensation reaction and yield are reported to be very long (overnight) and 73%, respectively.
  • the process is not, therefore, commercially viable for industrial scale production of entacapone and economical.
  • N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide is a mixture of two geometric isomers namely E- and Z-isomers (70 - 80% E-isomer and 30-20% Z-isomer) of the following formulae I and II, respectively :
  • This patent relates to a stable and crystallographically essentially pure polymorphic form A of E- isomer of N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide obtained by purifying the crude product by recrystallisation from lower aliphatic carboxylic acid such as formic acid or acetic acid with catalytic amount of hydrochloric or hydrobromic acid.
  • the purification procedure increases the process duration and renders it commercially unviable for industrial scale production.
  • WO 2005/063693 describes a process for the preparation of entacapone using 3-alkoxy-4- hydroxy-5-nitrobenzaldehyde.
  • WO 2005/070881 describes a process for the production of (E)-entacapone polymorphic form A.
  • 3,4Dihydroxy-5-nitrobenzaldehyde is condensed with N,N-diethylcyanoacetamide in the presence of a base like piperidine in alcohol like isopropanol.
  • the reaction mixture is poured into a mixture of aqueous ethyl acetate and water followed by pH adjustment with acetic acid.
  • the product is separated from the organic layer to yield (E) isomer of entacapone having 99.7% purity.
  • the condensation reaction itself is reported to be quite long (10 - 15 hours).
  • Novel polymorphic forms C and D of entacapone are disclosed in WO2005/066117.
  • 3,4Dihydroxy-5-nitrobenzaldehyde is condensed with N,N-diethylcyanoacetamide in the presence of a base like piperidine in isopropanol followed by addition of acetic acid and crystallization with a mixture of alcohols to obtain polymorphic form C.
  • Polymorphic form D is obtained from form C or form A by dissolution in solvents such as polar organic solvents aliphatic alcohols or sulfoxides.
  • WO 2005/063695 and WO 2005/063696 also disclose novel polymorphs C 5 D and E of Entacapone by crystallisation.
  • An object of the invention is to provide a process for the preparation of (E)-N, N-diethyl-2- cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide, which gives the product in high purity and good yield.
  • Another object of the invention is to provide a process for the preparation of (E)-N, N-diethyl- 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide, which reduces the process duration and is simple, easy and convenient to carry out and is commercially viable and economical.
  • Another object of the invention is to provide (E)-N, N-diethyl-2-cyano-3-(3,4-dihydroxy-5- nitrophenyl) acrylamide in very high purity and good yield.
  • Formula I comprising i) condensing 3,4-dihydroxy-5-nitro benzaldehyde with N,N-diethyl cyano acetamide in an organic solvent in the presence of an organic base and an acid under reflux conditions followed by distilling off the solvent under vacuum and treating the residue with a lower aliphatic carboxylic acid at 40 - 8O 0 C;
  • the organic solvent used in step (i) is selected from lower aliphatic alcohol like methanol, ethanol, n-propanol, isopropanol or mixtures thereof or is preferably ethanol.
  • the organic base used in step (i) is selected from piperidine morpholine, N-methyl morpholine or pyrrolidine or is preferably piperidine.
  • the acid used in step (i) is organic acid selected from lower aliphatic carboxylic acid or inorganic acid selected from sulfuric acid or hydrochloric acid.
  • the lower aliphatic carboxylic acid used in step (i) is preferably acetic acid or formic acid.
  • the residue in step (i) is treated at 65 0 C,
  • the chlorinated solvent used in step (ii) is selected from methylene chloride or chloroform or is preferably methylene chloride.
  • the organic solvent used in step (iii) is selected from polar and non-polar solvents such as alcohols, ketones, esters or mixtures thereof.
  • the organic solvent is preferably ester selected from methyl acetate, ethyl acetate, propyl acetate or mixtures thereof or is preferably ethyl acetate.
  • the mixture of organic alcohol and organic, acid used in step (iv) is selected from aliphatic alcohol like methanol, ethanol, n-propanol or isopropanol and lower aliphatic carboxylic acid like acetic acid, formic acid, methane sulfonic acid or trifluoro acetic acid or is preferably, methanol and acetic acid.
  • the molar ratio of the crude product to organic alcohol is 1: 8 and the crude product to organic acid is 1 :2.
  • the product namely N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide is recovered from the reaction mixture of step (iv) by filtering the reaction mixture, precipitating the product from the filtrate by gradually cooling the filtrate at 0-30 0 C preferably 10 - 50° C and drying the precipitate at 60 - 70° C preferably in an electric oven.
  • the process of the invention affords (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide in high purity ( > 99.8%) and in good yield (about 53.68%) with Z- isomer content ⁇ 0.5%.
  • the process duration is reduced and the process is simple, easy and convenient to carry out and is commercially viable and economical.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A process for the preparation of highly pure (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide (Entacapone). It comprises condensing3,4-dihydroxy-5-nitro benzaldehyde with N,N-diethyl cyano acetamide in an organic solvent in the presence of an organic base and an acid under reflux conditions followed by distilling off the solvent under vacuum and treating the residue with a lower aliphatic carboxylic acid at 40 - 8O0C. The resulting residue is extracted with a chlorinated solvent and the solvent is distilled off under vacuum. The resulting residue is extracted with an organic solvent to obtain crude N,N-diethyl-2-cyano-3-3,4-dihydroxy-5-nitrophenyl)acrylamide. The crude product N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide formed is treated with a mixture of organic alcohol and organic acid in the molar ratio of the crude product to organic alcohol 1:5 to 15 and crude product to organic acid 1:1 to 3 under reflux conditions.

Description

A process for the preparation of highly pure (E) N,N-Diethyl-2-Cyano-3-(3,4-dihydroxy- 5-nitro phenyl) acrylamide (Entacapone)
Technical Field
The invention relates to a process for the preparation of highly pure (E) N,N-diethyl-2-cyano- 3-(3,4-dihydroxy-5-nitro phenyl) acrylamide (Entacapone) of the formula I:
Figure imgf000002_0001
Formula I
Background and Prior Art
US 4,963, 590 describes catechol derivatives including N, N-diethyl-2-cyano-3-(3,4- dihydroxy-5-nitro phenyl) acrylamide as being useful in the treatment of diseases like central or peripheral nervous system disorders, Parkinson's disease or parkinsonian disorders.
Process for the preparation of N, N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitro phenyl) acrylamide comprises condensation of 3,4-dihydroxy-5-nitro benzaldehyde and N9N- hydrochloric diethyl cyanoacetamide in the presence of piperidine-acetate in dry ethanol (Example 100). The condensation reaction and yield are reported to be very long (overnight) and 73%, respectively. The process is not, therefore, commercially viable for industrial scale production of entacapone and economical.
US 5,135,950 reports that N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide is a mixture of two geometric isomers namely E- and Z-isomers (70 - 80% E-isomer and 30-20% Z-isomer) of the following formulae I and II, respectively :
Figure imgf000003_0001
Figure imgf000003_0002
Formula II
This patent relates to a stable and crystallographically essentially pure polymorphic form A of E- isomer of N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide obtained by purifying the crude product by recrystallisation from lower aliphatic carboxylic acid such as formic acid or acetic acid with catalytic amount of hydrochloric or hydrobromic acid. The purification procedure increases the process duration and renders it commercially unviable for industrial scale production.
WO 2005/063693 describes a process for the preparation of entacapone using 3-alkoxy-4- hydroxy-5-nitrobenzaldehyde.
WO 2005/070881 describes a process for the production of (E)-entacapone polymorphic form A. 3,4Dihydroxy-5-nitrobenzaldehyde is condensed with N,N-diethylcyanoacetamide in the presence of a base like piperidine in alcohol like isopropanol. The reaction mixture is poured into a mixture of aqueous ethyl acetate and water followed by pH adjustment with acetic acid. The product is separated from the organic layer to yield (E) isomer of entacapone having 99.7% purity. The condensation reaction itself is reported to be quite long (10 - 15 hours).
Novel polymorphic forms C and D of entacapone are disclosed in WO2005/066117.
3,4Dihydroxy-5-nitrobenzaldehyde is condensed with N,N-diethylcyanoacetamide in the presence of a base like piperidine in isopropanol followed by addition of acetic acid and crystallization with a mixture of alcohols to obtain polymorphic form C. Polymorphic form D is obtained from form C or form A by dissolution in solvents such as polar organic solvents aliphatic alcohols or sulfoxides.
WO 2005/063695 and WO 2005/063696 also disclose novel polymorphs C5 D and E of Entacapone by crystallisation.
Objects of the Invention
An object of the invention is to provide a process for the preparation of (E)-N, N-diethyl-2- cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide, which gives the product in high purity and good yield.
Another object of the invention is to provide a process for the preparation of (E)-N, N-diethyl- 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide, which reduces the process duration and is simple, easy and convenient to carry out and is commercially viable and economical.
Another object of the invention is to provide (E)-N, N-diethyl-2-cyano-3-(3,4-dihydroxy-5- nitrophenyl) acrylamide in very high purity and good yield.
Detailed Description of invention According to the invention there is provided a process for the preparation of highly pure (E)- N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide (Entacapone) of the formula I
Figure imgf000005_0001
Formula I comprising i) condensing 3,4-dihydroxy-5-nitro benzaldehyde with N,N-diethyl cyano acetamide in an organic solvent in the presence of an organic base and an acid under reflux conditions followed by distilling off the solvent under vacuum and treating the residue with a lower aliphatic carboxylic acid at 40 - 8O0C;
ii) extracting the residue with a chlorinated solvent and distilling off the solvent under vacuum;
iii) extracting the residue with an organic solvent to obtain crude N,N-diethyl-2- cyano-3-3,4-dihydroxy-5-nitrophenyl)acrylamide; and
iv) treating the crude product N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5- nitrophenyl) acrylamide with a mixture of organic alcohol and organic acid in the molar ratio of the crude product to organic alcohol 1:5 to 15 and crude product to organic acid 1:1 to 3 under reflux conditions.
The organic solvent used in step (i) is selected from lower aliphatic alcohol like methanol, ethanol, n-propanol, isopropanol or mixtures thereof or is preferably ethanol. The organic base used in step (i) is selected from piperidine morpholine, N-methyl morpholine or pyrrolidine or is preferably piperidine. The acid used in step (i) is organic acid selected from lower aliphatic carboxylic acid or inorganic acid selected from sulfuric acid or hydrochloric acid. The lower aliphatic carboxylic acid used in step (i) is preferably acetic acid or formic acid. Preferably, the residue in step (i) is treated at 650C,
The chlorinated solvent used in step (ii) is selected from methylene chloride or chloroform or is preferably methylene chloride.
The organic solvent used in step (iii) is selected from polar and non-polar solvents such as alcohols, ketones, esters or mixtures thereof. The organic solvent is preferably ester selected from methyl acetate, ethyl acetate, propyl acetate or mixtures thereof or is preferably ethyl acetate.
The mixture of organic alcohol and organic, acid used in step (iv) is selected from aliphatic alcohol like methanol, ethanol, n-propanol or isopropanol and lower aliphatic carboxylic acid like acetic acid, formic acid, methane sulfonic acid or trifluoro acetic acid or is preferably, methanol and acetic acid.
Preferably, the molar ratio of the crude product to organic alcohol is 1: 8 and the crude product to organic acid is 1 :2.
The product namely N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide is recovered from the reaction mixture of step (iv) by filtering the reaction mixture, precipitating the product from the filtrate by gradually cooling the filtrate at 0-300C preferably 10 - 50° C and drying the precipitate at 60 - 70° C preferably in an electric oven.
The process of the invention affords (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide in high purity ( > 99.8%) and in good yield (about 53.68%) with Z- isomer content < 0.5%. The process duration is reduced and the process is simple, easy and convenient to carry out and is commercially viable and economical.
The following experimental example is illustrative of the invention but not limitative of the scope thereof : Example 1
A mixture of 3,4-dihydroxy-5-nitro benzaldehyde (50Og), N,N-diethyl cyano acetamide
(575ml), acetic acid (375ml) and piperidine (500ml) in ethanol (4.51) were refluxed for 6 hrs. Ethanol was distilled off under vacuum and 1.5 1 of formic acid was added to the residue at
65° C and stirred for 30 mins at 65° C. The reaction mixture was cooled to R T and charged with methylene dichloride. The organic layer was separated and washed twice with 2 x 3.5 1 water. Methylene dichloride was distilled off under vacuum from the organic layer and the residue was treated with ethyl acetate 1.25 1. The yellow solid was filtered out from the solvent, washed with 1.25 1 ethyl acetate and dried in an electric oven at 60-70° C to obtain crude N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitro phenyl) acrylamide.
Yield of crude entacapone 495g (59.63 %), Purity 99.2++
Z- isomer 0.5%
The crude product (495 g), methanol (3960ml) and acetic acid (990ml) were refluxed for lhr.
The clear solution was filtered and the product was precipitated by gradually cooling the filtrate to 10-15° C. The solid was filtered out, washed twice with cold ethyl acetate
(2 x 990 ml) at 15°C_and dried in an electric oven at 60-70° C.
Yield of entacapone based on the crude product 445.5g (90 %). Purity 99.8%.
Z-isomer 0.02 %

Claims

1. A process for the preparation of highly pure (E)-N,N-diethyl-2-cyano-3-(3,4- dihydroxy-5-nitrophenyl) acrylamide (Entacapone) of the formula I
Figure imgf000008_0001
Formula I
comprising i) condensing 3,4-dihydroxy-5-nitro benzaldehyde with N,N-diethyl cyano acetamide in an organic solvent in the presence of an organic base and an acid under reflux conditions followed by distilling off the solvent under vacuum and treating the residue with a lower aliphatic carboxylic acid at 40 - 800C;
ii) extracting the residue with a chlorinated solvent and distilling off the solvent under vacuum;
iii) extracting the residue with an organic solvent to obtain crude N,N-diethyl-2- cyano-3-3,4-dihydroxy-5-nitrophenyl)acrylamide; and
iv) treating the crude product N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5- nitrophenyl) acrylamide with a mixture of organic alcohol and organic acid in the molar ratio of the crude product to organic alcohol 1:5 to 15 and crude product to organic acid 1:1 to 3 under reflux conditions.
2. The process as claimed in claim 1, wherein the organic solvent used in step (i) is selected from lower aliphatic alcohol like methanol, ethanol, n-propanol, iso-propanol or mixtures thereof or is preferably ethanol.
3. The process as claimed in claim 1, wherein organic base used in step (i) is selected from piperidine, morpholine, N-methyl morpholine or pyrrolidine or is preferably piperidine and the acid used in step (i) is selected from lower aliphatic carboxylic acid like acetic acid or formic acid or inorganic acid selected from hydrochloric acid or sulphuric acid or is preferably acetic acid or formic acid.
4. The process as claimed in claim 1, wherein the residue in step (i) is treated 65° C.
5. The process as claimed in claim 1, wherein the chlorinated solvent used ins tep (ii) is selected from chlorofom or methylene dichloride or is preferably methylene dichloride.
6. The process as claimed in claim 1, wherein the organic solvent used in step (iii) is selected from polar and non-polar solvents such as alcohols, ketones or esters or mixtures thereof or is preferably ester, preferably ethyl acetate.
7. The process as claimed in claim 1 wherein the mixture of organic alcohol and organic acid used in step (iv) is selected from aliphatic alcohol like methanol, ethanol, n- propanol or iso-propanol and lower aliphatic carboxylic acid like acetic acid, formic acid or trifluoro acetic acid or is preferably methanol and acetic acid.
8. The process as claimed in claim 1, wherein molar ratio of the crude product to alcohol is 1:8 and the crude product to organic acid is 1: 2.
9 N,N-diethyl-2-cyano-3-)3,4-dihydroxy-5-nitrophenyl) acrylamide of the formula 1
Figure imgf000009_0001
Formula I in high purity (> 99.8%) and in good yield (53.68%) prepared by the process as claimed in claim 1.
PCT/IN2005/000363 2005-11-09 2005-11-09 A process for the preparation of highly pure (e) n,n-diethyl-2-cyano-3-(3,4-dihydroxy- 5-nitro phenyl) acrylamide (entacapone) WO2007054950A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PCT/IN2005/000363 WO2007054950A1 (en) 2005-11-09 2005-11-09 A process for the preparation of highly pure (e) n,n-diethyl-2-cyano-3-(3,4-dihydroxy- 5-nitro phenyl) acrylamide (entacapone)
AT05826478T ATE445591T1 (en) 2005-11-09 2005-11-09 METHOD FOR PRODUCING HIGH PURITY (E)-N,N-DIETHYL-2-CYANO-3-(3,4-DIHYDRO-5-NITROPHENYL)ACRYLAMIDE (ENTACAPONE)
DE602005017204T DE602005017204D1 (en) 2005-11-09 2005-11-09 PROCESS FOR PREPARING HIGH-PURITY (E) -N, N-DIETHYL-2-CYANO-3- (3,4-DIHYDRO-5-NITROPHENYL) ACRYLAMIDE (ENTACAPONE)
US12/092,657 US20080319226A1 (en) 2005-11-09 2005-11-09 Process For the Preparation of Highly Pure (E) N,N-Diethyl-2-Cyano-3-(3,4-Dihydroxy-5-Nitro Phenyl) Acrylamide (Entacapone)
EP05826478A EP1945607B1 (en) 2005-11-09 2005-11-09 A process for the preparation of highly pure (e) n,n-diethyl-2-cyano-3-(3,4-dihydroxy- 5-nitro phenyl) acrylamide (entacapone)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2005/000363 WO2007054950A1 (en) 2005-11-09 2005-11-09 A process for the preparation of highly pure (e) n,n-diethyl-2-cyano-3-(3,4-dihydroxy- 5-nitro phenyl) acrylamide (entacapone)

Publications (1)

Publication Number Publication Date
WO2007054950A1 true WO2007054950A1 (en) 2007-05-18

Family

ID=36910913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000363 WO2007054950A1 (en) 2005-11-09 2005-11-09 A process for the preparation of highly pure (e) n,n-diethyl-2-cyano-3-(3,4-dihydroxy- 5-nitro phenyl) acrylamide (entacapone)

Country Status (5)

Country Link
US (1) US20080319226A1 (en)
EP (1) EP1945607B1 (en)
AT (1) ATE445591T1 (en)
DE (1) DE602005017204D1 (en)
WO (1) WO2007054950A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084031A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd An improved process for preparation of (2e)-2-cyano-3-(3,4- dihydroxy-5-nitrophenyl)n,n-diethyl-2-propenamide polymorphic form a
EP2251323A1 (en) * 2009-05-14 2010-11-17 F.I.S. Fabbrica Italiana Sintetici S.p.A. Method for the purification of entacapone
CN104402764A (en) * 2014-11-26 2015-03-11 千辉药业（安徽）有限责任公司 Preparation method for entacapone

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061259A (en) * 2015-08-25 2015-11-18 重庆植恩药业有限公司 Preparing method for entacapone A-type crystals

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2200109A (en) * 1986-11-28 1988-07-27 Orion Yhtymae Oy Catechol derivatives
US5135950A (en) * 1989-11-03 1992-08-04 Orion-Yhtyma Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
WO2005066117A1 (en) * 2003-12-29 2005-07-21 Wockhardt Limited Stable polymorphs of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide
WO2005070881A1 (en) * 2003-12-24 2005-08-04 Wockhardt Limited An efficient process for the manufacture of (e)-entacapone polymorphic form a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003288712B2 (en) * 2003-12-29 2010-11-04 Suven Life Sciences Ltd Alternative process for the preparation of entacapone
WO2005063696A2 (en) * 2003-12-31 2005-07-14 Cilag Ag Novel crystalline forms of entacapone and production thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2200109A (en) * 1986-11-28 1988-07-27 Orion Yhtymae Oy Catechol derivatives
US5135950A (en) * 1989-11-03 1992-08-04 Orion-Yhtyma Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
WO2005070881A1 (en) * 2003-12-24 2005-08-04 Wockhardt Limited An efficient process for the manufacture of (e)-entacapone polymorphic form a
WO2005066117A1 (en) * 2003-12-29 2005-07-21 Wockhardt Limited Stable polymorphs of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084031A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd An improved process for preparation of (2e)-2-cyano-3-(3,4- dihydroxy-5-nitrophenyl)n,n-diethyl-2-propenamide polymorphic form a
WO2009084031A3 (en) * 2007-12-03 2010-11-25 Neuland Laboratories Ltd An improved process for preparation of (2e)-2-cyano-3-(3,4- dihydroxy-5-nitrophenyl)n,n-diethyl-2-propenamide polymorphic form a
EP2251323A1 (en) * 2009-05-14 2010-11-17 F.I.S. Fabbrica Italiana Sintetici S.p.A. Method for the purification of entacapone
CN104402764A (en) * 2014-11-26 2015-03-11 千辉药业（安徽）有限责任公司 Preparation method for entacapone

Also Published As

Publication number Publication date
EP1945607B1 (en) 2009-10-14
ATE445591T1 (en) 2009-10-15
EP1945607A1 (en) 2008-07-23
US20080319226A1 (en) 2008-12-25
DE602005017204D1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
EP1945607B1 (en) A process for the preparation of highly pure (e) n,n-diethyl-2-cyano-3-(3,4-dihydroxy- 5-nitro phenyl) acrylamide (entacapone)
CA2601149C (en) Process of producing amorolfine
US8242268B2 (en) Production of bepromoline
CA2552099C (en) Improved process for the preparation of entacapone
US20080194623A1 (en) Method for the Synthesis of Quinoline Derivatives
WO2012026897A1 (en) A process for the preparation of imatinib base
CN112142604A (en) Preparation method of bromhexine hydrochloride and intermediate thereof
EP2035400B1 (en) Method for the preparation of salts of 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol (quetiapine)
WO2009081417A2 (en) Process for preparation of olopat adine hydrochloride
EP2097398A1 (en) Process of producing amorolfine
EP1682497A1 (en) Process for purifying mesotrione
US8044196B2 (en) Process for producing pure form of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
JP5232015B2 (en) Entacapone manufacturing method
CN109956899B (en) Preparation method of vitamin B6
EP2251323B1 (en) Method for the purification of entacapone
CN111039845A (en) Preparation method of 4-fluoro-7-bromoisatin
WO2009150669A1 (en) Process for controlling the growth of a raloxifene hydrochloride crystal
WO2008023380A1 (en) Improved and simplified procedure for the preparation of (e) n,n-diethyl-2-cyano-3(3,4-dihydroxy-5-nitrophenyl)acrylamide
CN111217711B (en) Method for separating and purifying N- (4-vinyl benzyl) -N, N-dimethyl amine
US8063251B2 (en) Process for the preparation of optically pure R (−) salbutamol and its pharmaceutically acceptable salts
JP4550740B6 (en) Entacapone improved manufacturing method
KR100342919B1 (en) A preparation and purification for trans isomer of tramadol hydrochloride
JP4313166B2 (en) Process for producing optically active β-trifluoromethyl-β-hydroxycarbonyl compound
JP2000198779A (en) Purification of 3-alkylflavanol derivative
CN112321412A (en) Preparation method of 2, 5-dimethoxy phenylacetic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 456/MUMNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005826478

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005826478

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12092657

Country of ref document: US